Mind Map¶
Interactive overview of the paper's logical structure. Click and drag to explore.
mindmap
root((The Price<br/>of Exclusion<br/>SME Set-Asides))
**Institutional Setting**
BEC platform
Sao Paulo state
Since 2005
~R$13B in 2019
4.8M item transactions
SME statute LC 123/2006
Revenue ceilings define ME/EPP
SME-only default below R$80K
Group 65 adherence ~43% post
Group 65 medical and hospital
~27% of transactions
Total-notice threshold kept it open
Two auction formats
Pregao descending clock
Drop-out prices observed
Convite first-price sealed
Cross-modality check
**Natural Experiment**
March 2018 mass take-up
PGE-SP item-level reading Dec 2017
Not a market shock
Group 65 switched
Open then SME-only
Other groups always treated
DiDiR design
Switched vs always-treated
**Identification**
Maintained IPV-clock
Drop-outs = willingness to supply
Load-bearing assumption
Krasnokutskaya UH correction
ICC 0.36 to 0.59
Cross-modality GPV
Partial discipline not proof
Structural sample
Pregao only
97,993 auctions
297,967 firm-auctions
**Reduced-form Benchmark**
Open ~10-11% cheaper
beta -0.108 to -0.148
Stable across windows
Timing and sign only
Not the structural magnitude
Distance widens +12 km
High-value items only
Null on low value
SME winner share falls
**Structural Decomposition**
Three pools S1 S2 S3
S1 open benchmark
S2 exclude non-SMEs
S3 post-policy SME pool
Lost discipline S2-S1
Protected-pool offset S3-S2
Exclusion share ~72%
SME entry roughly doubles
But does not replace discipline
Order-statistic not less aggressive bidding
**Welfare and Policy**
Static loss 28.9%
At lambda = 0.30
DWL plus MCPF
Implied SME weight 2.42
10% price preference
Near-zero static cost
Preserves price-forming pool
Less redistribution
Annual cost R$38 to 89M
Frontier
Exclusionary redistribution
vs preserving the pool
**Robustness**
Placebos null
HonestDiD survives M-bar
Lee bounds tight
Goodman-Bacon 100% clean 2x2
Sun-Abraham matches DDR
Synthetic control
Bootstrap CI 64.5 to 86.8%
Strict invariance 85%
Empirical bidder count 69%
Collusion screens
No post-policy shift
RAIS-validated SMEs
**Scope and Boundary**
Pharma is boundary case
Larger but model-sensitive
Four diagnostics fail
CMED split
Effect inside and outside 6531
Competition not pharma inflation